No support shown for the use of pycnogenol for chronic disorders

By Milly Dawson

The manufacturer of a dietary supplement made from French pine bark, Pycnogenol, markets it widely for the prevention or treatment of many chronic disorders, ranging from asthma to erectile dysfunction, but a recent systematic review found no sound basis for the claims.

“We found that no solid evidence exists to support health claims that are being made for the antioxidant supplement Pycnogenol,” said senior author Jimmy Volmink, M.D., Ph.D., Dean of the Faculty of Health Sciences at Stellenbosch University in South Africa and director of the SA Cochrane Centre, Medical Research Council of South Africa. “Only 15 randomized controlled trials…have evaluated the effects of Pycnogenol.” The manufacturer sponsored 11 of them.

Pycnogenol is derived from the bark of pine trees that grow only in southern France. It contains the antioxidant proanthocyanidin, which is present in fruits, red wine and chocolate.

Dietary supplements represent a multibillion industry, notes Volmink. “Steps are currently being taken in several countries to improve the regulation of the industry, in terms of quality, safety and the validity of health claims.” Meanwhile, consumers must interpret claims cautiously, he said.

The fifteen trials - performed in the USA, Europe, China and Iran - involved 791 participants. The disorders studied included , attention deficit hyperactivity disorder, chronic venous insufficiency, diabetes, erectile dysfunction, hypertension and osteoarthritis. Two trials were done with children; the rest with adults.

The new review's authors could draw no solid conclusions regarding benefits that many studies purported to find. The 15 trials exhibited poor quality, with small sample sizes (11 to 156 participants) and often inadequate blinding. Key results were sometimes missing for relevant outcomes and some trials provided results only for the treatment group taking Pycnogenol®, but not for controls.

Roberta W. Scherer, Ph.D., an associate scientist at the Johns Hopkins Bloomberg School of Public Health said, “A majority of the studies were funded by the manufacturer, leading to increased risk of bias.” She noted that because the trials had small samples, it is difficult to have confidence in the findings. The trials also examined diverse outcomes, making combining the results difficult or impossible. “Also, safety is hard to assess with small trials,” she said. “It’s not really shown” in small, short-term trials like those done on Pycnogenol.

Both scientists called for bigger, better studies of Pycnogenol before consumers can trust in its efficacy and safety.

More information: Schoonees A., Visser J., Musekiwa A., Volmink J. (2012). Pycnogenol® for the treatment of chronic disorders. The Cochrane Library, Issue 2.

add to favorites email to friend print save as pdf

Related Stories

New study: Pine bark significantly reduces menstrual pain

Jun 18, 2008

A new study reveals dysmenorrhea, a condition that causes extremely painful menstrual periods affecting millions of women each year, can be reduced naturally by taking Pycnogenol (pic-noj-en-all), pine bark extract from the ...

New study: pine bark extract boosts nitric oxide production

Oct 17, 2007

A study to be published in the October edition of Hypertension Research reveals Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, helps individuals by enhancing healthy ...

For a less biased study, try randomization

Apr 13, 2011

A new review of existing research confirms that the so-called “gold standard” of medical research — the randomized controlled study — provides a safeguard against bias.

Telehealth keeps asthmatics out of hospitals

Oct 06, 2010

Health care delivered via telephone or Internet might not improve the quality of life for people with mild asthma, but it could keep those with severe asthma out of the hospital, a new evidence review finds.

Recommended for you

Vaccine proves effective against deadly Middle East virus

15 hours ago

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

16 hours ago

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments